Compare First Citizens BancShares Inc (FCNCA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs TransMedics Group Inc — how do they compare? First Citizens BancShares Inc trades at $2,271.85 (market cap $25.04B), while TransMedics Group Inc trades at $87.59 (market cap $3.10B). The key difference: First Citizens BancShares Inc is far larger — about 8.1× TransMedics Group Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FCNCA | TMDX | |
|---|---|---|
Market Cap | $25.04B | $3.10B |
Sector | Sector/Thematic | Technology |
52-Week High | $2.25K | $150.42 |
52-Week Low | $1.64K | $61.99 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,258.55, up 1.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by positive cash flow trends and strategic expansions in commercial banking services. Recent news highlights institutional investments and new leadership appointments, reinforcing growth initiatives.
Outlook remains favorable due to consistent earnings outperformance and expanding business segments, though risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is mixed with a hold-heavy rating, but the stock offers value with upside to the $2,310 price target. Investors should weigh solid profitability against sector-specific headwinds.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
